JP2008532949A5 - - Google Patents

Info

Publication number

JP2008532949A5

JP2008532949A5 JP2007558266A JP2007558266A JP2008532949A5 JP 2008532949 A5 JP2008532949 A5 JP 2008532949A5 JP 2007558266 A JP2007558266 A JP 2007558266A JP 2007558266 A JP2007558266 A JP 2007558266A JP 2008532949 A5 JP2008532949 A5 JP 2008532949A5

Authority

JP

Japan

Prior art keywords

composition

antibody

humanized

residues

hla

Prior art date

2006-03-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 25
• 239000000427 antigen Substances 0.000 claims 9
• 102000036639 antigens Human genes 0.000 claims 9
• 108091007433 antigens Proteins 0.000 claims 9
• 239000012636 effector Substances 0.000 claims 8
• 239000012634 fragment Substances 0.000 claims 6
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
• 102000006354 HLA-DR Antigens Human genes 0.000 claims 4
• 108010058597 HLA-DR Antigens Proteins 0.000 claims 4
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
• 206010028980 Neoplasm Diseases 0.000 claims 3
• 150000001768 cations Chemical class 0.000 claims 3
• 239000003814 drug Substances 0.000 claims 3
• 102000004190 Enzymes Human genes 0.000 claims 2
• 108090000790 Enzymes Proteins 0.000 claims 2
• 241001529936 Murinae Species 0.000 claims 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
• 239000000032 diagnostic agent Substances 0.000 claims 2
• 229940039227 diagnostic agent Drugs 0.000 claims 2
• 239000002955 immunomodulating agent Substances 0.000 claims 2
• 230000002584 immunomodulator Effects 0.000 claims 2
• 229940121354 immunomodulator Drugs 0.000 claims 2
• 150000002632 lipids Chemical class 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
• JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 claims 1
• 108090000695 Cytokines Proteins 0.000 claims 1
• 108010044091 Globulins Proteins 0.000 claims 1
• 102000006395 Globulins Human genes 0.000 claims 1
• 241000282412 Homo Species 0.000 claims 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
• 108091034117 Oligonucleotide Proteins 0.000 claims 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
• 229910052768 actinide Inorganic materials 0.000 claims 1
• 150000001255 actinides Chemical class 0.000 claims 1
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
• 230000006907 apoptotic process Effects 0.000 claims 1
• 229910052785 arsenic Inorganic materials 0.000 claims 1
• 229910052789 astatine Inorganic materials 0.000 claims 1
• 229910052797 bismuth Inorganic materials 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 229910052802 copper Inorganic materials 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
• 229910052737 gold Inorganic materials 0.000 claims 1
• 239000005556 hormone Substances 0.000 claims 1
• 229940088597 hormone Drugs 0.000 claims 1
• 229940127121 immunoconjugate Drugs 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 229910052747 lanthanoid Inorganic materials 0.000 claims 1
• 150000002602 lanthanoids Chemical class 0.000 claims 1
• 229910052745 lead Inorganic materials 0.000 claims 1
• 229910052751 metal Inorganic materials 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 239000000693 micelle Substances 0.000 claims 1
• 239000002105 nanoparticle Substances 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 229940002612 prodrug Drugs 0.000 claims 1
• 239000000651 prodrug Substances 0.000 claims 1
• 229910052702 rhenium Inorganic materials 0.000 claims 1
• 229910052709 silver Inorganic materials 0.000 claims 1
• 229910052713 technetium Inorganic materials 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 239000003053 toxin Substances 0.000 claims 1
• 231100000765 toxin Toxicity 0.000 claims 1
• 230000007704 transition Effects 0.000 claims 1